MEP33008A - Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinases - Google Patents
Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinasesInfo
- Publication number
- MEP33008A MEP33008A MEP-330/08A MEP33008A MEP33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A
- Authority
- ME
- Montenegro
- Prior art keywords
- diseases
- joint
- matrixmetalloproteinases
- inhibitors
- inflammatory
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000006378 damage Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 208000036487 Arthropathies Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010067632 Cartilage atrophy Diseases 0.000 abstract 1
- 102000029816 Collagenase Human genes 0.000 abstract 1
- 108060005980 Collagenase Proteins 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010072970 Meniscus injury Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000003127 knee Anatomy 0.000 abstract 1
- 210000003041 ligament Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (de) | 2003-09-27 | 2003-09-27 | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
| PCT/EP2004/010248 WO2005030728A1 (de) | 2003-09-27 | 2004-09-14 | Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP33008A true MEP33008A (en) | 2010-10-10 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-330/08A MEP33008A (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinases |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (xx) |
| JP (1) | JP4861179B2 (xx) |
| KR (1) | KR20060086367A (xx) |
| CN (1) | CN1856478B (xx) |
| AR (1) | AR046165A1 (xx) |
| AT (1) | ATE550327T1 (xx) |
| AU (1) | AU2004275937A1 (xx) |
| BR (1) | BRPI0414594A (xx) |
| CA (1) | CA2539731A1 (xx) |
| DE (1) | DE10344936A1 (xx) |
| IL (1) | IL174040A0 (xx) |
| MA (1) | MA28075A1 (xx) |
| ME (1) | MEP33008A (xx) |
| MX (1) | MXPA06002927A (xx) |
| MY (1) | MY139830A (xx) |
| NO (1) | NO20061837L (xx) |
| NZ (1) | NZ546158A (xx) |
| PE (1) | PE20050432A1 (xx) |
| RS (1) | RS20060194A (xx) |
| RU (1) | RU2335494C2 (xx) |
| TW (1) | TW200520755A (xx) |
| UY (1) | UY28539A1 (xx) |
| WO (1) | WO2005030728A1 (xx) |
| ZA (1) | ZA200601501B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE102005002500A1 (de) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (xx) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (fr) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| RU2164914C2 (ru) * | 1995-11-13 | 2001-04-10 | Хехст Акциенгезелльшафт | ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ |
| NZ334253A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia |
| PL334846A1 (en) * | 1997-01-23 | 2000-03-27 | Hoffmann La Roche | Sulphamidic inhibitors of metaloproteases |
| DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
| DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/de not_active Withdrawn
-
2004
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/xx unknown
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/pt not_active IP Right Cessation
- 2004-09-14 EP EP04786944A patent/EP1670766B1/de not_active Expired - Lifetime
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/sr unknown
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/es active IP Right Grant
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/ko not_active Ceased
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/ru not_active IP Right Cessation
- 2004-09-14 AT AT04786944T patent/ATE550327T1/de active
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/de not_active Ceased
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/zh not_active Expired - Fee Related
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/ja not_active Expired - Fee Related
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/es not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/zh unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/es not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/es unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/fr unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ546158A (en) | 2008-11-28 |
| CA2539731A1 (en) | 2005-04-07 |
| KR20060086367A (ko) | 2006-07-31 |
| RU2006114352A (ru) | 2006-08-27 |
| WO2005030728A1 (de) | 2005-04-07 |
| MA28075A1 (fr) | 2006-08-01 |
| EP1670766B1 (de) | 2012-03-21 |
| AU2004275937A1 (en) | 2005-04-07 |
| RS20060194A (sr) | 2008-08-07 |
| EP1670766A1 (de) | 2006-06-21 |
| AR046165A1 (es) | 2005-11-30 |
| CN1856478B (zh) | 2010-05-26 |
| DE10344936A1 (de) | 2005-04-21 |
| MXPA06002927A (es) | 2006-06-14 |
| RU2335494C2 (ru) | 2008-10-10 |
| TW200520755A (en) | 2005-07-01 |
| JP4861179B2 (ja) | 2012-01-25 |
| CN1856478A (zh) | 2006-11-01 |
| PE20050432A1 (es) | 2005-07-21 |
| ATE550327T1 (de) | 2012-04-15 |
| NO20061837L (no) | 2006-06-01 |
| IL174040A0 (en) | 2006-08-01 |
| JP2007506690A (ja) | 2007-03-22 |
| ZA200601501B (en) | 2007-04-25 |
| MY139830A (en) | 2009-10-30 |
| BRPI0414594A (pt) | 2006-11-07 |
| UY28539A1 (es) | 2005-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050532A2 (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
| ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
| EA201290389A8 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| MA33909B1 (fr) | Pyrrolidinones accoles en tant d'inhibiteurs de syk | |
| BRPI0416692A (pt) | inibidores heterocìclicos de mek e métodos de emprego destes | |
| MY147449A (en) | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
| EA200400595A1 (ru) | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| YU44398A (sh) | Derivati supstituisanog benzensulfonamida kao prolekovi cox-2 inhibitora | |
| YU65804A (sh) | Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze | |
| CL43596B (es) | Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica. | |
| ITMI20031311A1 (it) | Formulazioni per il trattamento di disturbi artrosici. | |
| BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
| BR9307570A (pt) | Diéteres de catecol como inibidores seletivos de pdeiv | |
| BRPI0709581A8 (pt) | compostos de bicicloeteroarila como moduladores de px27 e seu uso | |
| UA92636C2 (xx) | Тетрагідропіримідоазепіни і їх застосування як модуляторів trpv1$тетрагидропиримидоазепины и их применение как модуляторов trpv1 | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| PT1049703E (pt) | Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo | |
| IS8175A (is) | Píperasín afleiður og aðferðir við notkun þeirra | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| BRPI0607583A2 (pt) | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos | |
| BR0306643A (pt) | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical | |
| MEP33008A (en) | Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinases | |
| MEP42908A (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds |